Low oxygen conditions (hypoxia) can impair essential physiological processes and cause cellular damage and death. We have shown that specific hypoxic conditions disrupt protein homeostasis in C. elegans, leading to protein aggregation and proteotoxicity. Here, we show that nutritional cues regulate this effect of hypoxia on proteostasis. Animals fasted prior to hypoxic exposure develop dramatically fewer polyglutamine protein aggregates compared to their…
Read More
Scientists at Benaroya Research Institute at Virginia Mason (BRI) are scrutinizing a newly identified population of human immune cells in the blood that appear to have everything in common with infection-fighting T cells isolated from the skin. The findings, published today in the journal Science Immunology, challenge current thinking that tissue-resident memory T cells are strictly retained in the tissue, in…
Read More
OncoSenX, Inc., a late preclinical-stage company developing therapeutics to kill cancer cells based on their genetics, today announced it has raised $3 million in pre-seed funding to advance its pipeline. “These funds will allow us to accelerate the preclinical research necessary for us to begin phase 1 clinical development,” said Matthew Scholz, chief executive officer of OncoSenX. “We believe our…
Read More
James Heath, PhD., is president and professor at the Institute for Systems Biology in Seattle. He also has the position of Professor of Molecular and Medical Pharmacology at UCLA, and he has directed the NCI-funded NSB Cancer Center since 2005. The Heath group works on translating P4 medicine from benchtop to bedside, with a focus on oncology. They are particularly…
Read More
Type III interferon (IFN-λ) is important for innate immune protection at mucosal surfaces and has therapeutic benefit against influenza A virus (IAV) infection. However, the mechanisms by which IFN-λ programs adaptive immune protection against IAV are undefined. Here we found that IFN-λ signaling in dendritic cell (DC) populations was critical for the development of protective IAV-specific CD8+ T cell responses. Mice…
Read More
Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) entering HCT with poor-risk features1,2,3. When HCT does produce prolonged relapse-free survival, it commonly reflects graft-versus-leukemia effects mediated by donor T cells reactive with antigens on leukemic cells4. As graft T cells have not been selected for leukemia specificity and…
Read More
New findings show how a genetically aberrant, fused protein promotes a rare form of liver cancer in adolescents and young adults. The researchers also saw that a certain mix of drugs could target the fused protein and the enzymes that it recruits.  In the lab, this drug combination slowed down the uncontrolled growth of cells carrying the liver cancer mutation.…
Read More

Dr. Meghan Koch named 2019 Rita Allen Foundation Scholar

Dr. Meghan Koch, an immunologist at Fred Hutchinson Cancer Research Center, has been named a 2019 Rita Allen Foundation Scholar. She studies how interactions between mother and infant influence infant growth and development. The Koch Lab particularly seeks to understand how immune factors passed from mother to baby shape its developing microbial communities and immune system, and how these effects influence growth.…
Read More
  Today, President Donald J. Trump announced the recipients of the Presidential Early Career Award for Scientists and Engineers (PECASE).  The PECASE is the highest honor bestowed by the United States Government to outstanding scientists and engineers who are beginning their independent research careers and who show exceptional promise for leadership in science and technology. Established in 1996, the PECASE…
Read More
Learn about the newly funded 2019-2020 Alzheimer’s Disease Research Center pilot projects. These one-year projects encourage investigators to use ADRC resources to advance the understanding, diagnosis, or treatment of Alzheimer’s disease. As published in Dimensions Magazine – Spring 2019 Douglas Barthold, PhD, Research Assistant Professor, Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, UW Department of Pharmacy Type II diabetes is a known…
Read More